Literature DB >> 12657124

Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University.

E Steiner1, O Eicher, J Sagemüller, M Schmidt, H Pilch, B Tanner, J G Hengstler, M Hofmann, P G Knapstein.   

Abstract

The aim of this study was to evaluate the biologic outcome of endometrial carcinomas as compared to clinical and pathologic parameters and to identify multivariate independent prognostic factors. Charts were abstracted from patients with endometrial carcinoma from 1985 to 1995. Data on clinicopathologic variables, adjuvant treatment, site of recurrence, and survival were collected. chi2 test was used to test association between variables. Kaplan-Maier method was used for survival analysis and Cox proportional hazards model for multiple regression analysis. Univariate analysis revealed that FIGO stage, tumor grade, depth of myometrial invasion, biochemical analysis of progesterone receptor status, age, additional diabetes mellitus, lymph node metastasis, and type of tumor were significantly associated with the overall-survival. For disease-free interval, FIGO stage, tumor grade, depth of myometrial invasion, biochemical analysis of progesterone receptor status, lymph node metastasis, and type of tumor were also significantly associated. Multivariate analysis revealed that FIGO stage, tumor grading, tumor type, depth of myometrial invasion, and biochemically measured progesterone receptor status were associated significantly with overall survival. A significant correlation as independent prognostic factors were also seen for recurrence free interval for FIGO stage, tumor grade, and biochemical progesterone receptor status. In multivariate statistical analysis we identified FIGO stage, tumor type, tumor grade, biochemical analysis of progesterone receptor status, and depth of myometrial invasion as independent prognostic factors for overall survival, and FIGO stage, biochemical analysis of progesterone receptor status, and tumor grade as independent prognostic factors for recurrence-free interval.

Entities:  

Mesh:

Year:  2003        PMID: 12657124     DOI: 10.1046/j.1525-1438.2003.13021.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  18 in total

1.  Progesterone receptor gene variants and risk of endometrial cancer.

Authors:  Tracy A O'Mara; Paul Fahey; Kaltin Ferguson; Louise Marquart; Diether Lambrechts; Evelyn Despierre; Ignace Vergote; Frederic Amant; Per Hall; Jianjun Liu; Kamila Czene; Timothy R Rebbeck; Shahana Ahmed; Alison M Dunning; Catherine S Gregory; Mitul Shah; Penelope M Webb; Amanda B Spurdle
Journal:  Carcinogenesis       Date:  2010-12-10       Impact factor: 4.944

2.  Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.

Authors:  Hakan Karagol; Pinar Saip; Kazim Uygun; Seden Kucucuk; Adnan Aydiner; Erkan Topuz
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy.

Authors:  Lan Xiao; Yue-bo Yang; Xiao-mao Li; Cheng-fang Xu; Tian Li; Xiao-yun Wang
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-20       Impact factor: 4.553

4.  Prognostic significance of elongator protein 3 expression in endometrioid adenocarcinoma.

Authors:  Yi Wang; Jun-Ichiro Ikeda; Nur Rahadiani; Suhana Mamat; Yutaka Ueda; Tian Tian; Takayuki Enomoto; Tadashi Kimura; Katsuyuki Aozasa; Eiichi Morii
Journal:  Oncol Lett       Date:  2011-09-22       Impact factor: 2.967

Review 5.  Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis.

Authors:  Bethany B Barone; Hsin-Chieh Yeh; Claire F Snyder; Kimberly S Peairs; Kelly B Stein; Rachel L Derr; Antonio C Wolff; Frederick L Brancati
Journal:  JAMA       Date:  2008-12-17       Impact factor: 56.272

6.  Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.

Authors:  Silvia Darb-Esfahani; Areeg Faggad; Aurelia Noske; Wilko Weichert; Ann-Christin Buckendahl; Berit Müller; Jan Budczies; Annika Röske; Manfred Dietel; Carsten Denkert
Journal:  J Cancer Res Clin Oncol       Date:  2008-12-24       Impact factor: 4.553

7.  Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis.

Authors:  Joanna D Stewart; Rosemarie Marchan; Michaela S Lesjak; Joerg Lambert; Roland Hergenroeder; James K Ellis; Chung-Ho Lau; Hector C Keun; Gerd Schmitz; Juergen Schiller; Mandy Eibisch; Christian Hedberg; Herbert Waldmann; Ekkehart Lausch; Berno Tanner; Jalid Sehouli; Jens Sagemueller; Hagen Staude; Eric Steiner; Jan G Hengstler
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-08       Impact factor: 11.205

8.  Role of the progesterone receptor for paclitaxel resistance in primary breast cancer.

Authors:  M Schmidt; E Bremer; D Hasenclever; A Victor; M Gehrmann; E Steiner; I B Schiffer; S Gebhardt; H-A Lehr; M Mahlke; M Hermes; A Mustea; B Tanner; H Koelbl; H Pilch; J G Hengstler
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640

Review 9.  Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.

Authors:  Yanli Zhang; Dong Zhao; Changguo Gong; Fengmei Zhang; Jing He; Wei Zhang; Yulan Zhao; Jing Sun
Journal:  World J Surg Oncol       Date:  2015-06-25       Impact factor: 2.754

10.  Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients.

Authors:  Alvaro Tejerizo-García; Jesús S Jiménez-López; José L Muñoz-González; Sara Bartolomé-Sotillos; Laura Marqueta-Marqués; Gregorio López-González; José F Pérez-Regadera Gómez
Journal:  Onco Targets Ther       Date:  2013-09-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.